Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Like many pharma stocks, Eli Lilly (NYSE ... Of course, by that time, Lilly and Novo Nordisk may see competitors emerge. For example, Viking Therapeutics is studying its dual GIP/GLP-1 receptor ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Rhumbline Advisers lifted its stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX – Free Report) by 9.1% during the 4th quarter, Holdings Channel.com reports.The institutional investor owned 36,384 ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other low risk stocks. Risk is a key consideration in investing and portfolio management ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) has achieved complete skin clearance after three years in 50% of patients with moderate-to-severe atopic dermatitis (AD) in a Phase III trial. The US ...

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on Monday.

Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...

Eli Lilly has announced a central nervous system research tie-up with UK biotech Evox Therapeutics, which focuses on drug engineering using vesicles to deliver drugs to targets. These tiny ...